Keck School Faculty

Gino In
Gino In
Assistant Professor of Clinical Medicine
Medicine
GNH 3821 Health Sciences Campus Los Angeles
Gino K. In, MD, MPH, is a medical oncologist who specializes in solid tumor and cutaneous oncology. He completed his fellowship training in hematology and oncology at the University of Southern California, Keck School of Medicine, where he was the chief medical oncology fellow. He subsequently joined the USC Norris Comprehensive Cancer Center, and now serves as Assistant Professor of Clinical Medicine in the Division of Oncology, and Assistant Professor of Dermatology. Dr. In’s research focus includes the multi-disciplinary management of melanoma and other skin cancers, including cutaneous squamous cell carcinoma, basal cell carcinoma and Merkel cell carcinoma. He has a specific interest in non-UV related melanoma subtypes and intratumoral therapies. Dr. In is the lead primary investigator for cutaneous oncology clinical trials at USC, including studies through the National Cancer Institute, California Cancer Consortium, and Southwest Oncology Group.

Concurrent radiation therapy with programmed cell death protein 1 inhibition leads to a complete response in advanced cutaneous squamous cell carcinoma JAAD Case Rep. 2019 Sep; 5(9):763-766. . View in PubMed

Skin cancer and dermatoses in a majority Hispanic population of solid organ transplant recipients J Am Acad Dermatol. 2019 Aug 07. . View in PubMed

Two synchronous malignancies: nodular melanoma and renal cell carcinoma in a patient with an underlying germline BRCA2 mutation BMJ Case Rep. 2019 Jun 20; 12(6). . View in PubMed

Cetuximab as a Component of Multimodality Treatment of High-Risk Cutaneous Squamous Cell Carcinoma: A Retrospective Analysis From a Single Tertiary Academic Medical Center Dermatol Surg. 2019 02; 45(2):254-267. . View in PubMed

Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance Nat Commun. 2019 04 12; 10(1):1693. . View in PubMed

Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma JAAD Case Rep. 2018 Nov; 4(10):1004-1006. . View in PubMed

Eccrine Porocarcinoma: New Insights and a Systematic Review of the Literature Dermatol Surg. 2018 10; 44(10):1247-1261. . View in PubMed

Development of metastatic brain disease involves progression through lung metastases in EGFR mutated non-small cell lung cancer Converg Sci Phys Oncol. 2017 Sep; 3(3). . View in PubMed

Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations Ther Adv Med Oncol. 2017 Aug; 9(8):533-550. . View in PubMed

Development of metastatic brain disease involves progression through lung metastases in EGFR mutated non-small cell lung cancer Convergent Science Physical Oncology. 2017; 3(3). . View in PubMed

Skin Cancer Prevention Among Hispanics: a Review of the Literature Epidemiology. 2017. . View in PubMed

Chemotherapy for Good-Risk Nonseminomatous Germ Cell Tumors: Current Concepts and Controversies Urol Clin North Am. 2015 Aug; 42(3):347-57. . View in PubMed

Emerging Chemotherapy Agents in Lung Cancer: Nanoparticle Therapeutics for Non-Small Cell Lung Cancer Transl Cancer Res. 2015; 4(4):340-355. . View in PubMed

Powered by SC CTSI
Go to Top